Augustine Asset Management Inc. increased its position in shares of Pfizer, Inc. (NYSE:PFE) by 8.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,421 shares of the biopharmaceutical company’s stock after buying an additional 1,441 shares during the period. Augustine Asset Management Inc.’s holdings in Pfizer were worth $652,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in PFE. Orbimed Advisors LLC raised its position in shares of Pfizer by 46.3% in the fourth quarter. Orbimed Advisors LLC now owns 5,167,900 shares of the biopharmaceutical company’s stock worth $167,853,000 after buying an additional 1,635,700 shares in the last quarter. Paulson & CO. Inc. bought a new position in shares of Pfizer during the fourth quarter worth about $11,439,000. E&G Advisors LP raised its position in shares of Pfizer by 6.8% in the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock worth $2,130,000 after buying an additional 3,940 shares in the last quarter. Prentiss Smith & Co. Inc. raised its position in shares of Pfizer by 1.7% in the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 250 shares in the last quarter. Finally, Carroll Financial Associates Inc. raised its position in shares of Pfizer by 33.9% in the first quarter. Carroll Financial Associates Inc. now owns 197,820 shares of the biopharmaceutical company’s stock worth $6,767,000 after buying an additional 50,045 shares in the last quarter. Hedge funds and other institutional investors own 70.10% of the company’s stock.

Pfizer, Inc. (NYSE PFE) traded down 0.30% during mid-day trading on Friday, reaching $33.32. 6,504,539 shares of the company’s stock were exchanged. The stock has a market cap of $198.85 billion, a P/E ratio of 24.37 and a beta of 1.00. The stock has a 50-day moving average price of $33.43 and a 200-day moving average price of $33.30. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the business earned $0.64 earnings per share. The company’s revenue was down 1.9% compared to the same quarter last year. On average, analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is currently 94.12%.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/pfizer-inc-nysepfe-position-increased-by-augustine-asset-management-inc.html.

PFE has been the subject of a number of recent analyst reports. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and increased their target price for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reiterated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research report on Monday, July 31st. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Jefferies Group LLC reiterated a “neutral” rating and issued a $35.00 target price (up previously from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $37.77.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.